These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 25755001)

  • 1. Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.
    Charpentier C; Lee GQ; Rodriguez C; Visseaux B; Storto A; Fagard C; Molina JM; Katlama C; Yazdanpanah Y; Harrigan PR; Descamps D
    J Antimicrob Chemother; 2015 Jul; 70(7):2090-6. PubMed ID: 25755001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen.
    Charpentier C; Roquebert B; Colin C; Taburet AM; Fagard C; Katlama C; Molina JM; Jacomet C; Brun-Vézinet F; Chêne G; Yazdanpanah Y; Descamps D;
    AIDS; 2010 Nov; 24(17):2651-6. PubMed ID: 20802293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression.
    Gantner P; Morand-Joubert L; Sueur C; Raffi F; Fagard C; Lascoux-Combe C; Salmon D; Amiel C; Lambert-Niclot S; Fofana DB; Viard JP; Fafi-Kremer S; Rouzioux C; Avettand-Fenoel V; Ghosn J
    J Antimicrob Chemother; 2016 Mar; 71(3):751-61. PubMed ID: 26676973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of different analysis pipelines for the detection of HIV-1 minority resistant variants.
    Perrier M; Désiré N; Storto A; Todesco E; Rodriguez C; Bertine M; Le Hingrat Q; Visseaux B; Calvez V; Descamps D; Marcelin AG; Charpentier C
    PLoS One; 2018; 13(6):e0198334. PubMed ID: 29856864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.
    Fourati S; Charpentier C; Amiel C; Morand-Joubert L; Reigadas S; Trabaud MA; Delaugerre C; Nicot F; Rodallec A; Maillard A; Mirand A; Jeulin H; Montès B; Barin F; Bettinger D; Le Guillou-Guillemette H; Vallet S; Signori-Schmuck A; Descamps D; Calvez V; Flandre P; Marcelin AG;
    J Antimicrob Chemother; 2015 May; 70(5):1507-12. PubMed ID: 25558077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial).
    Charpentier C; Fagard C; Colin C; Katlama C; Molina JM; Jacomet C; Visseaux B; Taburet AM; Brun-Vézinet F; Chêne G; Yazdanpanah Y; Descamps D;
    PLoS One; 2013; 8(1):e53621. PubMed ID: 23349724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of the virological response to etravirine in clinical practice: Comparison of three genotype algorithms.
    Cotte L; Trabaud MA; Tardy JC; Brochier C; Gilibert RP; Miailhes P; Trépo C; André P
    J Med Virol; 2009 Apr; 81(4):672-7. PubMed ID: 19235860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an HIV-1-infected child using ultra-deep sequencing.
    Stefic K; Salmona M; Capitao M; Splittgerber M; Maakaroun-Vermesse Z; Néré ML; Bernard L; Chaix ML; Barin F; Delaugerre C
    J Antimicrob Chemother; 2017 Mar; 72(3):850-854. PubMed ID: 27999055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance.
    Fun A; Leitner T; Vandekerckhove L; Däumer M; Thielen A; Buchholz B; Hoepelman AIM; Gisolf EH; Schipper PJ; Wensing AMJ; Nijhuis M
    Retrovirology; 2018 Jan; 15(1):1. PubMed ID: 29304821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection.
    Nicot F; Saliou A; Raymond S; Sauné K; Dubois M; Massip P; Marchou B; Delobel P; Izopet J
    J Clin Virol; 2012 Oct; 55(2):107-13. PubMed ID: 22818969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy.
    Lambert-Niclot S; Flandre P; Valantin MA; Peytavin G; Sayon S; Morand-Joubert L; Delaugerre C; Algarte-Genin M; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2012 Jun; 67(6):1470-4. PubMed ID: 22396434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir.
    Perrier M; Visseaux B; Landman R; Joly V; Todesco E; Yazdanpanah Y; Calvez V; Marcelin AG; Descamps D; Charpentier C
    J Antimicrob Chemother; 2018 Jan; 73(1):173-176. PubMed ID: 29077926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels.
    Kozal MJ; Chiarella J; St John EP; Moreno EA; Simen BB; Arnold TE; Lataillade M
    Antivir Ther; 2011; 16(6):925-9. PubMed ID: 21900725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.
    Yazdanpanah Y; Fagard C; Descamps D; Taburet AM; Colin C; Roquebert B; Katlama C; Pialoux G; Jacomet C; Piketty C; Bollens D; Molina JM; Chêne G;
    Clin Infect Dis; 2009 Nov; 49(9):1441-9. PubMed ID: 19814627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
    Delaugerre C; Peytavin G; Dominguez S; Marcelin AG; Duvivier C; Gourlain K; Amellal B; Legrand M; Raffi F; Costagliola D; Katlama C; Calvez V
    J Med Virol; 2005 Nov; 77(3):345-50. PubMed ID: 16173015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA and DNA Sanger sequencing versus next-generation sequencing for HIV-1 drug resistance testing in treatment-naive patients.
    Alidjinou EK; Deldalle J; Hallaert C; Robineau O; Ajana F; Choisy P; Hober D; Bocket L
    J Antimicrob Chemother; 2017 Oct; 72(10):2823-2830. PubMed ID: 29091197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group M.
    Alessandri-Gradt E; Morgand M; Delaugerre C; Peytavin G; Sellier P; Simon F; Plantier JC
    AIDS; 2015 Jun; 29(10):1271-3. PubMed ID: 26035328
    [No Abstract]   [Full Text] [Related]  

  • 19. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.
    Canducci F; Barda B; Ceresola E; Spagnuolo V; Sampaolo M; Boeri E; Nozza S; Cossarin F; Galli A; Gianotti N; Castagna A; Lazzarin A; Clementi M
    Clin Microbiol Infect; 2011 Jun; 17(6):928-34. PubMed ID: 20854427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of HIV-1 multi-drug-resistant treatment-experienced participants treated with etravirine, raltegravir and boosted darunavir: towards drug-reduced regimen? ANRS CO3 Aquitaine Cohort 2007-2018.
    Nyamankolly E; Bellecave P; Wittkop L; Le Marec F; Duffau P; Lazaro E; Vareil MO; Tumiotto C; Hessamfar M; Cazanave C; Perrier A; Leleux O; Bonnet F; Neau D
    Int J Antimicrob Agents; 2023 Jan; 61(1):106696. PubMed ID: 36470511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.